Abstract: Certain compounds, structurally related to natural compounds which can be extracted i.a. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives. These compounds have the structural formula wherein the substituents are as defined in the specification.

Abstract: The present invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines and their use for inhibiting liver glycogen phosphorylase.

Abstract: The present invention provides novel crystalline (−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate useful for reducing or preventing bone loss as well as pharmaceutical compositions containing the same. A process for preparing (−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate is described.

Abstract: The present invention relates to 4H-thieno[3,2-e]-1,2,4-thiadiazine derivatives of the general formula: wherein X, Y, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

Abstract: A pharmaceutical preparation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature.

Abstract: Methods of dyeing a material, comprising treating the material with a dyeing system which comprises (a) one or more mono-, di- or polycyclic aromatic or heteroaromatic compounds, and (b) (i) a hydrogen peroxide source and an enzyme exhibiting peroxidase activity or (ii) an enzyme exhibiting oxidase activity on the one or more aromatic or heteroaromatic compounds; wherein the material is a fabric, yarn, fiber, garment or film made of cotton, diacetate, flax, linen, lyocel, polyacrylic, synthetic polyamide, polyester, ramie, rayon, tencel, or triacetate.

Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia.

Abstract: The invention is directed to agents used in the retention of color values on fabrics formed from cellulose fibers (color clarification agents) and to a method for treatment of such fabrics. The method comprises treating a colored fabric with a cellulase and a polymer selected from the group consisting of a polyalkylene oxide graft polymer, a polyamino acid polymer, and a carboxylated polysaccharide polymer in an amount effective to preserve the color of the fabric after at least one wash cycle.

Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with an antibody raised against a purified xylanase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components e.g. in the preparation of feed, in baking, in the paper and pulp industry and in connection with separation of wheat into starch and gluten.

Abstract: This invention relates to a directly compressible enzyme powder produced by mixing a liquid enzyme preparation with a suitable carrier, using the principle of wet granulation, whereby the step of freeze drying and spray-drying is avoided. The resulting enzyme powder has extraordinary good compression qualities and may directly be tabletted.

Abstract: The present invention provides a new stable pharmaceutical composition containing tiagabine hydrochloride as active ingredient.

Abstract: The invention relates to modified polypeptides with reduced allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (M.sub.r) in the range of 1 kDa and 60 kDa. The modified polypeptide are produced using a process including the step of conjugating from 1 to 30 polymer molecules with the parent polypeptide. Further the invention relates to compositions comprising said polypeptides and further ingredients normally used in e.g. detergents, including dishwashing detergents and soap bars, household article, agrochemicals, personal care products, cosmetics, toiletries, oral and dermal pharmaceuticals, composition for treating textiles, and compositions used for manufacturing food and feed. Finally the invention is directed to uses of polypeptides with reduced allergenicity or compositions thereof for reducing the allergenicity of productsfor a vast number of industrial applications.

Abstract: An .alpha.-amylase characterized by having a specific activity at least 25% higher than the specific activity of Termamyl.RTM. at a temperature in the range of 25.degree. C. to 55.degree. C. and at a pH value in the range of pH 8 to pH 10.

Abstract: A DNA construct comprising a DNA sequence encoding an enzyme exhibiting protease activity, which DNA sequence comprises the DNA sequence shown in SEQ ID No. 1 or 2 or an analog of any of these sequences being at least 80% homologous to the DNA sequence shown in SEQ ID No. 1 or 2. The proteases encoded by the DNA sequences have an acid pH optimum.

Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. These peptide derivatives have the formula:A--B--C--D--E (--F).sub.pwherein A, B, C, D, E, F and p are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation as well as improved growth hormone releasing activity.

Abstract: A pharmaceutical formulation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. The formulation may be used to treat a patient with a disorder associated with growth hormone deficiency.

Abstract: The invention relates to a process for providing a bleached look in the color density of the surface of dyed fabric, especialy cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and a phenothiazine or phenoxazine enhancing agent represented by formula (I).

Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.

Abstract: The present invention relates to a novel metalloprotease obtainable from a fungus having increased proteolytic activity. Additionally, the invention related to isolated nucleic acid fragments encoding said metalloprotease as well as vectors, DNA constructs, and recombinant host cells comprising said nucleic acid fragments.

Abstract: The present invention relates to a mutant DNA sequence encoding protein phosphatase 1 G-subunit, wherein a mutation of G to T occurs in the position of codon 905 of the coding sequence, a method of detecting a mutation in the gene encoding protein phosphatase 1 G-subunit, as well as a diagnostic composition and a test kit for use in the method.